Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.
Advertisement

Related Content

Describing An Investigational Drug On Your Website? Don’t Be Definitive About The Data, FDA Says
IND Promotion Quandary Again Trips Up Burzynski Research Institute
Equetro Web Pages Omit Risk Info, Make Unsupported Claims On Depression, FDA Says
CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs
CEL-SCI Warning Letter Shows Pitfalls Of Website Presentations Of Investigational Drugs
ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA
ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA
Clinical Trial Investigators Cannot Promote A Drug Prior To Its Approval, FDA Asserts

Topics

Advertisement
UsernamePublicRestriction

Register

PS072538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel